Insys Therapeutics Inc (INSY)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Insys Therapeutics Inc (INSY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013922
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems. The company’s flagship product, Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients. Its lead product candidate Syndros (dronabinol oral solution) is intendedfor the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. Insys uses its proprietary sublingual spray technology to develop its products. The company offers its products to oncologists, pain specialists and supportive care centers. It has operations in the US and offers its products through third party agreements in international markets. Insys is headquartered in Chandler, Arizona, the US.

Insys Therapeutics Inc (INSY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Insys Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Insys Therapeutics Enters into Licensing Agreement with Senzer 12
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 13
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 14
Equity Offering 15
Insys Therapeutics Completes IPO For US$36.8 Million 15
Insys Therapeutics Inc – Key Competitors 17
Insys Therapeutics Inc – Key Employees 18
Insys Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Nov 02, 2017: INSYS Therapeutics Reports Third Quarter 2017 Results 20
Aug 03, 2017: Insys Therapeutics Reports Second Quarter 2017 Results 21
May 09, 2017: Insys Therapeutics Reports First Quarter 2017 Results 22
Apr 03, 2017: Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results 23
Nov 03, 2016: Insys Therapeutics Reports Third Quarter 2016 Results 25
Aug 03, 2016: Insys Therapeutics Reports Second Quarter 2016 Results 26
Apr 28, 2016: Insys Therapeutics Reports First Quarter 2016 Results 27
Feb 23, 2016: Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results 28
Corporate Communications 30
Oct 29, 2017: INSYS Therapeutics Announces Resignation of Patrick P. Fourteau from Board of Directors 30
Oct 29, 2017: INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors 31
Jul 18, 2017: Insys Therapeutics Appoints Andrew G. Long as Chief Financial Officer 32
May 16, 2017: Insys Therapeutics Announces Chief Financial Officer Transition 33
May 04, 2017: Insys Therapeutics Appoints Rohit Vishnoi to Board of Directors 34
Apr 24, 2017: Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs 35
Mar 27, 2017: Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 36
Jan 09, 2017: Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board 37
Sep 21, 2016: Insys Therapeutics Announces CEO Succession Plan 38
Legal and Regulatory 39
Oct 29, 2017: INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017 39
Product News 40
07/31/2017: Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription 40
05/24/2017: Insys Therapeutics Announces FDA Final Product Label for Syndros 41
Product Approvals 42
Mar 23, 2017: DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug 42
Jul 05, 2016: Insys Therapeutics Announces FDA Approval of Syndros 43
Mar 22, 2016: Insys Therapeutics Announces 3-Month Extension of PDUFA Date for Syndros 44
Clinical Trials 45
Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD 45
Other Significant Developments 46
Jan 25, 2016: Insys Therapeutics Releases Statement on Its Patient Services Center 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Insys Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Insys Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Insys Therapeutics Enters into Licensing Agreement with Senzer 12
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 13
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 14
Insys Therapeutics Completes IPO For US$36.8 Million 15
Insys Therapeutics Inc, Key Competitors 17
Insys Therapeutics Inc, Key Employees 18
Insys Therapeutics Inc, Other Locations 19
Insys Therapeutics Inc, Subsidiaries 19

★海外企業調査レポート[Insys Therapeutics Inc (INSY)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ringier AG:企業の戦略的SWOT分析
    Ringier AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Smith & Nephew plc:企業のM&A・事業提携・投資動向
    Smith & Nephew plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Smith & Nephew plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Experian PLC (EXPN):企業の財務・戦略的SWOT分析
    Experian PLC (EXPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Canon Medical Systems Corp:企業の戦略的SWOT分析
    Canon Medical Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sagemcom SAS:企業の戦略的SWOT分析
    Sagemcom SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Pierre & Vacances SA (VAC):企業の財務・戦略的SWOT分析
    Pierre & Vacances SA (VAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Janssen Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Janssen Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Janssen Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Nippon Express Co Ltd (9062):企業の財務・戦略的SWOT分析
    Nippon Express Co Ltd (9062) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Digimarc Corp (DMRC):企業の財務・戦略的SWOT分析
    Summary Digimarc Corp (Digimarc) is a technology company that offers develops solutions, license intellectual property and provides development services to businesses and government. The company offers products such as digimarc discover, online image safeguards and digimarc guardian. Digimarc’s Disc …
  • Celsion Corp (CLSN):医療機器:M&Aディール及び事業提携情報
    Summary Celsion Corp (Celsion) is an oncology company that strives to develop a portfolio of new cancer treatments, including directed chemotherapies, RNA or DNA based therapies and immunotherapies. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), T …
  • Tejas Networks Ltd (TEJASNET):企業の財務・戦略的SWOT分析
    Tejas Networks Ltd (TEJASNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Columbus Energy Resources PLC (CERP):石油・ガス:M&Aディール及び事業提携情報
    Summary Columbus Energy Resources PLC (Columbus Energy), formerly LGO Energy Plc is an oil and gas exploration and development company. The company acquires, explores, develops and produces oil and gas properties. It operates oil and gas assets in Trinidad including the South West Peninsula licenses …
  • Betco Corp:企業の戦略的SWOT分析
    Betco Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Steris Corp-医療機器分野:企業M&A・提携分析
    Summary Steris Corp (Steris), formerly Innovative Medical Technologies, a subsidiary of Steris Plc, is a medical device company that offers infection prevention and other procedural products and services. The company offers surgical equipment and image management, sterile processing equipment, surgi …
  • Tobira Therapeutics Inc (TBRA)-医療機器分野:企業M&A・提携分析
    Summary Tobira Therapeutics Inc (Tobira), formerly Regado Biosciences, Inc, which develops and commercializes therapies for the treatment of to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. Its pipeline products include Cenicriviroc (CVC) and Ev …
  • Magellan Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Magellan Diagnostics Inc (Magellan Diagnostics), formerly ESA Inc, a subsidiary of Meridian Bioscience Inc, is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services. The company’s products include LeadCare II, LeadCa …
  • Fonterra Co-operative Group Ltd:企業の戦略・SWOT・財務情報
    Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Whitehaven Coal Ltd:企業のM&A・事業提携・投資動向
    Whitehaven Coal Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Whitehaven Coal Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Bio Techne Corp (TECH):製薬・医療:M&Aディール及び事業提携情報
    Summary Bio Techne Corp (Bio Techne), formerly Techne, develops, produces, and markets biotechnology products and scientific tools to understand biological processes and drive research. The company’s portfolio encompasses native and recombinant proteins, monoclonal and polyclonal antibodies, immunoa …
  • ITC Holdings Corp.:電力:M&Aディール及び事業提携情報
    Summary ITC Holdings Corp. (ITC Holdings), an indirect subsidiary of Fortis Inc, is an independent electricity transmission company. It owns, operates, maintains, and invests in transmission infrastructure. The company harnesses system integrity and reliability, reduces transmission constraints, all …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆